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I n t R o d u c t I o n
In the pancreatic β cell, ATP-sensitive K+ (KATP) chan-
nels play a critical role in coupling membrane excit-
ability to glucose-stimulated insulin secretion, and 
thereby maintaining blood glucose in a narrow range. 
Gain-of-function (GOF) mutations in the pore-form-
ing Kir6.2 subunit or in the regulatory sulfonylurea 
receptor 1 (SUR1) subunit have been identified as the 
commonest cause of human neonatal diabetes melli-
tus (NDM; Gloyn et al., 2004b; Vaxillaire et al., 2004; 
Sperling, 2006; Hamilton-Shield, 2007; Polak and 
Cavé, 2007). Normally, increased glucose metabolism 
elevates intracellular [ATP]/[ADP] ratio inhibiting 
KATP channels, leading to membrane depolarization, 
opening of voltage-dependent Ca2+ channels, and an 
increase in intracellular [Ca2+], which, in turn, triggers 
insulin secretion (Nichols, 2006). Antidiabetic sulfo-
nylurea drugs promote insulin secretion by binding to 
the SUR1 subunit of the KATP channel, independently 
of the metabolic state of the cell (Ashcroft and Grib-
ble, 1999). Sulfonylurea drugs have been widely used 
in type 2 diabetes treatment and, recently, successfully 
used to treat NDM patients with KATP-GOF mutations 
(Pearson et al., 2006).
There are two Kir6 subunit–encoding genes 
(KCNJ8, Kir6.1 and KCNJ11, Kir6.2). Kir6.2 is a major 
component of pancreatic β cell KATP channels: we 
previously demonstrated development of profound 
neonatal diabetes in mice constitutively expressing 
Kir6.2-GOF mutations in pancreatic β cells (Koster et 
al., 2000; Remedi et al., 2009). These mice rapidly de-
velop severe diabetes followed by the development of 
secondary consequences of systemic diabetes, includ-
ing marked loss of insulin content and β cell mass 
(Girard et al., 2009; Remedi et al., 2009; Wang et al., 
2014), consequences that are completely avoided by 
maintenance of normoglycemia at disease onset (Re-
medi et al., 2009, 2011; Benninger et al., 2011) and 
dramatically reversed by intensive insulin therapy 
(Wang et al., 2014).
Kir6.1 was originally cloned from the pancreas 
(Inagaki et al., 1995), but neither the presence of 
Kir6.1-containing KATP channels in the β cell nor any-
contribution to insulin secretion has been established. 
Given the high sequence similarity between Kir6.1 and 
Kir6.2, and based on the development of severe diabe-
tes in Kir6.2-GOF mice (Girard et al., 2009; Remedi et 
al., 2009), we hypothesized that pancreatic expression 
of GOF mutations in the Kir6.1 subunit of the channel 
would also decrease insulin secretion. To probe this, we 
generated transgenic mice expressing Kir6.1 mutations 
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under Cre-recombinase control to specifically express 
the transgene in the tissue of interest. Single mutant 
Kir6.1[G343D], double mutant Kir6.1[G343D,Q53R], 
and WT Kir6.1 transgenic mice (Li et al., 2013) were 
crossed with rat-insulin-promoter Cre mice (Rip-Cre 
[Herrera, 2002]) to generate pancreatic β cell–specific 
Rip-Kir6.1[GD], Rip-Kir6.1[GD,QR], and Rip-
Kir6.1[WT] mice, respectively. Single mutant Rip-
Kir6.1[GD] mice show glucose intolerance, and double 
mutant Rip-Kir6.1[GD,QR] mice develop as severe dia-
betes as do Rip-Kir6.2-GOF transgenic mice. We also 
expressed Kir6.1 mutants in bacterial artificial chromo-
somes (BACs) in order to express the transgene only in 
tissues where the Kir6.1 gene is normally present. Strik-
ingly, BAC-Kir6.1[GD] mice show similar glucose intol-
erance to Rip-Kir6.1[GD] mice. The results have 
important implications for the molecular basis of pan-
creatic KATP channels and for the potential role of 
KCNJ8 (Kir6.1) gene variants in insulin secretory con-
trol and the development of diabetes.
M At e R I A l s  A n d  M e t h o d s
Human islets and study approval
Isolated cadaver-derived human islets were obtained 
from the Integrated Islet Distribution Program (IIDP) 
sponsored by the National Institute of Diabetes and Di-
gestive and Kidney Diseases and the JDRF-sponsored 
Islets for Research Program at Washington University 
(JDRF-31-2008-382). The IIDP uses only cadaver donors 
that have consented to research. The Washington Uni-
versity Medical Center (WUMC) Human Studies Com-
mittee (HSC) Institutional Review Board (IRB) 
approved all studies involving the use of isolated cadav-
er-derived human islets (approval number: 93-0068). 
The IRB exempted the study from HIP AA compliance 
based on the regulatory definition of human subject. 
Review date: 7/8/2004; review committee: 08 MRCR. 
Human islet donor data: four independent organ do-
nors, two males and two females; mean age 35 yr, mean 
purity 85.8%, and mean viability 92.9%.
Quantitative real-time PCR (qRT-PCR) analysis
Mouse islets were isolated and immediately processed 
for RNA isolation. Upon arrival, human islets were col-
lected by centrifugation, cleaned, and hand-selected in 
CMRL media under a stereomicroscope (SMZ745 sys-
tem; Nikon) and immediately processed for RNA isola-
tion to perform qRT-PCR. Cellular RNA was isolated 
using the RNeasy Mini kit (QIA GEN), and DNA was re-
moved using DNase1 RNase-free solution (QIA GEN). 
cDNA was prepared from RNA using the High Capacity 
cDNA Reverse Transcription kit (Applied Biosystems), 
and qRT-PCR was performed using StepOne software 
2.3 and TaqMan primers (Applied Biosystems). Actin 
was used as a reference gene.
Generation of CX1-Kir6.1[WT], CX1-Kir6.1[GD], CX1-
Kir6.1[GD,QR], BAC-Kir6.1[WT], and BAC-Kir6.1[GD] 
transgenic mice
Inducible Kir6.1-GOF transgenes were generated by 
subcloning WT, Kir6.1[Gly343Asp] (G343D), and 
Kir6.1[Gly343Asp,Gln53Arg] (G343D,Q53R)-poly-A 
cDNAs downstream of the CX-1 promoter in the 
pBS-CX1-LEL vector (a gift from G. Owens, Univer-
sity of Virginia, Charlottesville, VA), which contains 
the chicken β-actin (CX1) promoter, followed by 
the eGFP coding region (including a stop codon), 
flanked by two loxP sites, to create CX1-Kir6.1[WT], 
CX1-Kir6.1[G343D], and CX1-Kir6.1[G343D,Q53R] 
transgenic constructs (Li et al., 2013). 6–11 founder 
mice carrying (1) Kir6.1[WT], Kir6.1[G343D], or 
Kir6.1[G343D,Q53R] were generated and bred 
to homogeneity by multiple (6×) backcrosses to 
C57BL/6J mates as previously described (Li et al., 
2013). These mice were crossed with rat-insulin-pro-
moter Cre (Rip-Cre) mice to generate pancreatic β 
cell–specific Rip-Kir6.1[GD], Rip-Kir6.1[GD,QR], 
and Rip-Kir6.1[WT] mice.
A mouse BAC containing the Kir6.1 genomic locus 
(BAC ID# RP23-159E3) was used to generate the 
Kir6.1[WT] and Kir6.1[G343D] BAC transgenes via 
galK-based homologous recombination in bacteria. 
Positive clones from the first round of recombineer-
ing were subjected to a second round of recombineer-
ing to remove the galK gene, leaving behind only the 
desired mutations. Positive recombinants were iden-
tified via directional PCR, restriction digest, and se-
quencing. Mutant and WT BAC DNA were prepared 
using a modified QIA GEN maxi-prep, which was 
dot dialyzed on 0.1  µM EMD Millipore filters using 
BAC injection buffer. The Washington University 
Transgenic Vectors Core generated the Kir6.1[WT] 
and Kir6.1[G343D] BAC transgenes, and microin-
jection services were provided by the Washington 
University Mouse Genetics Core. Kir6.1−/− (Kir6.1 
knockout [Kir6.1KO]) mice, originally generated 
by Miki et al. (2002), were obtained as a gift from 
S. Seino (Kobe University Graduate School of Medi-
cine, Kobe, Japan).
Animal study approval
All procedures complied with the standards for the care 
and use of animal subjects as stated in the Guide for the 
Care and Use of Laboratory Animals (National Insti-
tutes of Health publication No. 85-23, revised 1996).
Blood glucose
Tail blood was assayed for glucose content using a Glu-
cometer Elite Xl meter (Bayer Corp). The limit of de-
tection was 600 mg/dl, and glucose at or above this level 
was recorded as 600 mg/dl but considered to be a lower 
limit of the true value.
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Glucose tolerance test (GTT)
Intraperitoneal GTT was performed in 12-h fasted 7-wk-
old mice by injection of a bolus of glucose (1.5  g/kg 
body weight). Blood was taken at different times and 
assayed for glucose content as above.
Islet isolation
8-wk-old mice were anesthetized with 0.2 ml isoflurane 
and killed by cervical dislocation. The bile duct was can-
nulated and perfused with Hank’s balanced salt solu-
tion (Sigma-Aldrich) containing collagenase (0.3 mg/
ml, Collagenase Type XI; Sigma-Aldrich). Pancreata 
were removed and digested for 5 min at 37°C, hand 
shaken, and washed three times in cold Hanks’ solu-
tion. Islets were isolated by hand under a dissecting 
SMZ745 microscope, and pooled islets were maintained 
overnight in CMRL-1066 (5.6 mM glucose) culture me-
dium (GIB CO) supplemented with 10% fetal calf 
serum, 100 U/ml penicillin, and 100 µg/ml streptomycin.
Insulin secretion
After overnight incubation in low glucose (5.6  mM) 
CMRL-1066 medium, islets (10 per well in 12-well 
plates) were preincubated in glucose-free CMRL-1066 
plus 3 mM glucose and then incubated for 60 min at 
37°C in CMRL-1066 plus different glucose concentra-
tions, 1 µM glibenclamide, or 30 mM KCl, as indicated. 
After the incubation period, the medium was removed 
and assayed for insulin release. Insulin secretion was 
measured using a Rat Insulin radioimmunoassay ac-
cording to manufacturer’s procedure (RIA; EMD Milli-
pore; Remedi et al., 2009). Plasma insulin was measured 
using Singulex Erenna method (similar to insulin en-
zyme-linked immunosorbent assay) at the Core Labora-
tory for Clinical Studies, Washington University in St. 
Louis. Experiments were repeated in triplicate.
Isolated islet fluorescence imaging
Freshly isolated islets from 8-wk-old mice were imaged 
for eGFP, a reporter of transgene expression, using an 
inverted florescent microscope (LSM 510 laser-scan-
ning confocal microscope; ZEI SS). Images were taken 
with 20× objectives using the same settings for both con-
trol and transgenic islets.
86Rb+ efflux experiments
Isolated islets were preincubated for 6 h with 86Rb+ (ru-
bidium chloride 1.5 mCi/ml; GE Healthcare). Loaded 
islets were placed in microcentrifuge tubes (30 per 
group) and washed twice with RPMI-1640 medium at 
37°C (Sigma-Aldrich). 86Rb+ efflux was assayed by re-
placing the bathing solution with Ringer’s solution with 
metabolic inhibitor (MI), with or without 1 µM gliben-
clamide. MI solution contained 2.5 mg/ml oligomycin 
and 1 mM 2-deoxyglucose, together with 10 mM tetra-
ethylammonium to block voltage-gated K+ channels and 
10 µM nifedipine to block Ca2+ entry. The other solu-
tions were different glucose concentrations (1, 7, and 
20  mM glucose). The bathing solution was replaced 
with fresh solution every 5 min over a 50-min period 
and counted in a scintillation counter. 86Rb efflux in the 
presence of glucose and drugs were fit by a single expo-
nential, in which the rate constant (k) is proportional to 
the K+ (Rb+)-conductance in the islet membranes.
Statistics
Data are presented as mean ± SEM. Differences among 
groups were tested using unpaired t test to assess signif-
icance. Differences were assumed to be significant in 
each case if P < 0.05, and nonsignificant differences are 
not indicated in the figures.
R e s u lt s
Kir6.1 is expressed in mouse and human 
pancreatic islets
Although Kir6.1 subunits are prominent components 
of vascular KATP channels (Flagg et al., 2010), the cDNA 
was originally cloned from pancreatic islets (Inagaki et 
al., 1995), but there was little consideration of the pres-
ence of this subunit in insulin-secreting cells. The latter 
studysuggest that Kir6.1 is naturally expressed in islets, 
raising the possibility that Kir6.1 subunits might con-
tribute to native islet KATP function. WT and Kir6.1KO 
mouse islets were subjected to qRT-PCR. As predicted, 
robust Kir6.1 signals, in addition to Kir6.2 signals, were 
detected in mouse WT islets (Fig. 1 A), but there was no 
Kir6.1 signal detectable (at up to 50 cycles) in Kir6.1KO 
islets (Fig.  1  B), confirming the validity of the Kir6.1 
signal in WT islets. Expression of Kir6.2 was not differ-
ent between WT and Kir6.1KO islets (Fig. 1 B). Impor-
tantly, human islets obtained from cadaveric organ 
donors also showed a robust Kir6.1 transcript level 
(Fig. 1 C). Thus, the Kir6.1 subunit of the KATP channel 
is natively present in both mouse and human pan-
creatic islets.
β cell expression of ATP-insensitive Kir6.1-
containing KATP channels
To study the effects of Kir6.1 subunits of the KATP chan-
nel in vivo, we have generated novel mice that express 
either the Kir6.1 WT (Kir6.1[WT]) or a Kir6.1-GOF, sin-
gle mutant G343D (Kir6.1[GD]) or double mutant 
G343D/Q53R (Kir6.1[GD,QR]) transgenes under 
Cre-recombinase control (Li et al., 2013). Global Cx1 
Kir6.1[WT], Kir6.1[GD], and Kir6.1[GD,QR] mice ex-
press GFP fluorescence ubiquitously in the whole body, 
but after tissue-specific Cre-recombination, these mice 
lose fluorescence only in the tissue of interest (Li et al., 
2013). Specific expression in pancreatic β cells was 
achieved by crossing Kir6.1 transgenic mice with Rip-
Cre mice. Fig. 2 shows marked loss of fluorescence in 
o
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pancreatic islets from double transgenic Rip-Kir6.1[WT] 
(A), Rip-Kir6.1[GD] (B), and Rip-Kir6.1[GD,QR] (C; as 
an indication of transgene expression), compared with 
bright fluorescent islets from single Kir6.1[WT], 
Kir6.1[GD], and Kir6.1[GD,QR] transgenic mice (lack-
ing recombination and absence of transgene expres-
sion). Littermate control mice in all experiments below 
include pooled WT, single transgenic Rip-Cre, and sin-
gle transgenic Kir6.1[GD] or Kir6.1 [GD,QR] mice. In 
each case, no significant differences were found be-
tween these genotypes when independently tested.
Diabetes in Kir6.1-GOF mutant mice
GOF mutations in the Kir6.1 subunit of the KATP chan-
nel result in either glucose intolerance (Rip-
Kir6.1[GD]) or frank diabetes (Rip-Kir6.1[GD,QR]), 
mimicking the consequences of weak or more signifi-
cant expression of Kir6.2-GOF transgenes (Koster et 
al., 2000, 2005; Remedi et al., 2009). 7-wk-old double 
transgenic Rip-Kir6.1[GD] mice showed higher fed 
glucose than littermate control mice (Fig. 2 B). They 
also demonstrate increased fasting blood glucose and a 
mildly impaired glucose tolerance, accompanied by re-
duced circulating plasma insulin after glucose chal-
lenge with respect to control littermates (Fig.  3  B). 
Importantly, however, 2 out of 10 Rip-Kir6.1[GD] mice 
showed diabetes with dramatically high fasting blood 
glucose levels and a marked impairment of glucose tol-
erance (Fig.  2  B). Strikingly, all Rip-Kir6.1[GD,QR] 
mice developed severe diabetes (Fig. 2 C) with mark-
edly impaired glucose tolerance, as the result of signifi-
cantly reduced plasma insulin levels in response to 
Figure 1. Kir6.1 transcript is present in primary human and mouse islets. qRT-PCR in mouse and human islets. (A and B) Repre-
sentative traces of transcript amplification versus cycle number from mouse islets. (A) Insulin is represented in red, Kir6.2 in green, 
and Kir6.1 in blue. Actin was used as housekeeping gene and is shown in orange. Same color lines are duplicates from the same 
sample. (B) Comparative amplification traces for Kir6.2 (green) and Kir6.1 (blue) genes in WT and Kir6.1KO islets (n = 5 mice of each 
genotype, each sample was run in duplicates). Kir6.2 transcripts are present at similar levels in both WT and Kir6.1KO islets, but 
Kir6.1 transcript is only detected in WT islets and not in Kir6.1KO islets. (C) Each color represents traces for Kir6.1 transcript and 
the corresponding actin transcript in islets from independent human cadaveric organ donors. (D) Mean crossing threshold (Ct) for 
transcripts from mouse and human islets. Data represent mean ± SEM, n = 4 independent batches of human islets and n = 5 mice 
from each genotype. Samples were run in duplicates.
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glucose challenge (Fig. 3 C). Importantly, however, and 
as expected, overexpression of WT Kir6.1 subunits in 
Rip-Kir6.1[WT] mice did not result in increased blood 
glucose or glucose intolerance (Figs. 2 A and 3A), sug-
gesting that impaired glucose tolerance and diabetes 
are promoted by Kir6.1-GOF and are not an artifactual 
consequence of overexpressed transgenic protein 
levels per se.
We have also generated BAC Kir6.1 transgenic (BAC-
Kir6.1[GD]) and WT (BAC-Kir6.1[WT]) mice (see Ma-
terials and methods). Because the BAC constructs are 
expected to contain the native regulatory elements of 
the Kir6.1 gene, with no exogenous promoter, the trans-
gene should be expressed under native promoter con-
trol, and hence only in tissues where the Kir6.1 subunit 
is normally present. Strikingly, BAC-Kir6.1[GD] mice 
show higher blood glucose levels, reduced circulating 
insulin in fed conditions (Fig. 4 A), and impaired glu-
cose tolerance with reduced plasma insulin at 30 min, 
compared with BAC-Kir6.1[WT] mice (Fig. 4 B). The 
similar phenotype of BAC-Kir6.1[GD] mice to Rip-
Kir6.1[GD] mice implicates native Kir6.1 in controlling 
glucose tolerance and, as shown below, most likely by 
regulating β cell secretion directly. Given the likely low 
level of Kir6.1 in the β cell, under normal conditions, 
WT Kir6.1 is unlikely to play a major role, and we de-
tected no significant effects of Kir6.1KO on blood glu-
cose (Kir6.1KO: 108 ± 2.02 mg/dl and WT: 119 ± 2.59 
mg/dl), glucose tolerance, or KATP conductance as-
sessed by Rb efflux (not depicted).
Figure 2. Increased blood glucose in Kir6.1-GoF 
mice. (A–C, left) Representative intrinsic GFP fluores-
cence in freshly isolated islets from transgenic mice. 
High fluorescence in transgenic islets indicates the 
presence of the Kir6.1 transgene (Kir6.1[x], Control), 
and loss of fluorescence in transgenic β cells within is-
lets after Cre-recombination (Rip-Kir6.1[x]) indicates 
actual expression of the transgene specifically in these 
cells. Bars, 10 µm. (right) Fed blood glucose over time 
after weaning in Rip-Kir6.1[WT] (A, black), single mu-
tant Rip-Kir6.1[GD] (B, green), and double mutant 
Rip-Kir6.1[GD,QR] (C, red) with respect to their control 
littermates (white). Data represent mean ± SEM, n = 
8–10 animals in each group. Significant differences (*, P 
< 0.05) between transgenic and control littermate mice 
are indicated (t test).
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Kir6.1-GOF mouse islets show decreased 
responsivity to glucose challenge but 
maintained KCl response
Consistent with hyperglycemia in BAC-Kir6.1[GD] mice 
shown above, there was also a modest but significant 
reduction in glucose-dependent insulin secretion from 
isolated BAC-Kir6.1[GD] islets, with respect to controls 
(Fig.  5). Importantly, however, BAC-Kir6.1[GD] still 
responded to glibenclamide, although with an smaller 
response, and responded with similar maximal secre-
tion in response to K+ depolarization (KCl; Fig. 5), in-
dicating no marked impairment of secretory processes 
downstream of the electrical signal. As expected, BAC-
Kir6.1[WT] mice showed similar glucose- and gliben-
clamide-dependent secretion to control littermate 
mice (Fig. 5).
Kir6.1-GOF islets exhibit a reduction in total KATP 
channel density but sensitivity to glibenclamide drugs
K conductance in intact BAC-Kir6.1[WT] and BAC-
Kir6.1[GD] transgenic was assessed by 86Rb+ efflux in 
the presence of different [glucose] and glibenclamide. 
Fig. 6 A shows representative sample fluxes from both 
genotypes. Fluxes were fit by single exponentials and 
reciprocal rate constants (normalized to 1 mM glucose) 
are plotted in Fig.  6  B. In BAC-Kir6.1[WT] islets, the 
flux is glucose sensitive, being almost completely re-
duced to basal (i.e., flux in glibenclamide) in the pres-
ence of 20 mM glucose. In contrast, the BAC-Kir6.1[GD] 
flux is markedly less glucose sensitive, with substantial 
glibenclamide-sensitive (i.e., KATP-dependent) flux still 
present even at 20 mM glucose (Fig. 6 B). Interestingly, 
the absolute maximum rate constant (in 1 mM glucose) 
Figure 3. Glucose tolerance in 
Kir6.1 transgenic mice. (A–C) GTT on 
12-h fasted (left) and plasma insulin 
(right) in Rip-Kir6.1[WT] (A, black), Rip-
Kir6.1[GD] (B, green), and Rip-Kir6.1[G-
D,QR] (C, red) and control littermates 
at 7 wk of age. Blood glucose concen-
tration versus time after injection of 
1.5  g/kg glucose. Plasma insulin was 
determined in fasted mice (time 0) and 
30 min after glucose challenge during 
GTT. Data represent mean ± SEM, n = 
8–10 animals in each group. For Rip-
Kir6.1[GD], 2 of 10 animals, with fasting 
blood glucose >300 mg/dl, are shown 
individually (dashed line), and the re-
maining 8 of 10 animals, with fasting 
blood glucose <200 mg/dl, are shown 
as mean data (solid line). Significant 
differences (*, P < 0.05) between trans-
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was slightly lower in BAC-Kir6.1[GD] islets (0.029 ± 
0.010 min−1) than in control islets (0.042 ± 0.004 min−1), 
which may reflect reduced maximal KATP conductance 
as a result of lower single channel current in Kir6.1-con-
taining channel pores (Nichols, 2006).
d I s c u s s I o n
Kir6.1-containing channels are present in both human 
and mouse islets: Implications for human diabetes
Although Kir6.1 subunits (encoded by KCNJ8) are prom-
inent components of vascular KATP channels (Flagg et al., 
2010), the Kir6.1 cDNA was originally cloned from pan-
creatic islets (Inagaki et al., 1995), yet there has been lit-
tle subsequent consideration of any role or even the 
likely presence of this subunit in insulin-secreting cells. 
Our expression analysis shows that Kir6.1 transcript is 
clearly present in both human and mouse islets (Fig. 1) 
and, importantly, that there is no Kir6.1 transcript de-
tected in Kir6.1KO mouse islets and no effect of Kir6.1 
deletion on Kir6.2 transcript levels (Fig. 1). Other exper-
iments (supplementary data in Pagliuca et al. [2014]) 
have also found KCNJ8 gene expression in human β cells 
isolated from cadaveric donors and in β cells generated 
from human pluripotent stem cells. Furthermore, tran-
scriptome data from 10 human cadaveric organ donors 
show that KCNJ8 (Kir6.1, ranked 5,410) was second only 
to KCNJ11 (Kir6.2, ranked 3,486) as the highest ex-
pressed Kir subunit in β cells (genes ranked in descend-
ing order according to magnitude of expression, i.e., 
insulin was ranked 1; Segerstolpe et al., 2016). Together, 
these studies highlight the presence of Kir6.1 in pancre-
atic β cells and raise the exciting possibility that alter-
ations in Kir6.1 expression or channel properties could 
affect insulin secretion and thereby play a modulatory 
role in human diabetes.
Diabetes induced by GOF mutation in the Kir6.1 
subunit of the KATP channel
In the pancreatic β cell, KATP channels are the critical link 
between glucose metabolism and insulin secretion, high-
lighted by the fact that GOF mutations in the pore-form-
ing Kir6.2 and regulatory SUR1 subunits of the KATP 
channel (KATP-GOF) are the main cause of human NDM 
(Gloyn et al., 2004a,b; Vaxillaire et al., 2004; Massa et al., 
2005). Mice expressing Kir6.2-GOF mutations specifi-
cally in pancreatic β cells reiterate key features of NDM 
(Koster et al., 2000; Girard et al., 2009; Remedi et al., 
2009). Here, we have shown that pancreatic expression 
of a severely ATP-insensitive Kir6.1 mutation in 
Rip-Ki6.1[GD,QR] mice also results in reduced circulat-
ing plasma insulin and development of severe diabetes, 
whereas expression of a mildly ATP-insensitive mutation 
in Rip-Kir6.1[GD] mice leads to development of glucose 
intolerance, comparable with the phenotypes of strong 
and mild GOF mutations in Kir6.2 in mice and humans 
(Koster et al., 2000, 2006; Gloyn et al., 2004b; Flanagan et 
al., 2007; Remedi et al., 2009, 2011; Villareal et al., 2009).
Figure 4. Fed blood glucose and glu-
cose tolerance in BAc-Kir6.1 mice. (A) 
Fed blood glucose (left) and plasma 
insulin (right) in BAC-Kir6.1[WT] (blue), 
BAC-Kir6.1[GD] (pink), and control 
littermate (white) mice. (B) Glucose 
(left) and insulin levels (right) at time 0 
(fasting) and 30 min after glucose chal-
lenge in BAC-Kir6.1[WT] (blue), BAC-
Kir6.1[GD] (pink), and control littermate 
(white) mice. Data represent mean ± 
SEM, n = 10–15 animals in each group. 
Significant differences (*, P < 0.05) 
between transgenic and control litter-
mate mice under the same condition 
and (#, P < 0.05) on the same genotype 
mice under different conditions are 
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Our data show that deliberate expression of Kir6.1-
GOF mutations in β cells can result in their ready incor-
poration into functional β cell KATP channels and hence 
in the modulation of insulin secretion. One potential 
caveat is that transgenic expression of mutant subunit 
proteins may result in gross islet abnormalities, but the 
fact that no significant differences were found between 
Rip-Kir6.1[WT] mice and littermate control mice (Figs. 
2 A and 3A) suggests no major abnormalities as a result 
of transgene overexpression per se. More importantly, 
BAC-Kir6.1-GOF transgenic mice (but not BAC-
Kir6.1[WT] transgenic mice), which express the trans-
gene under control of the native promoter, also show 
higher glucose levels and reduced circulating plasma 
insulin in fed conditions (Fig.  4  A). BAC-Kir6.1-GOF 
show glucose intolerance with decreased insulin secre-
tion 30 min after glucose challenge (Fig. 4 B) and a spe-
cific reduction in glucose-sensitive insulin secretion in 
vitro (Fig.  5). The overall KATP conductance in BAC-
Kir6.1-GOF transgenic islets exhibits reduced glucose 
sensitivity, with substantial glibenclamide-sensitive Rb 
flux still present at high (20  mM) [glucose] (Fig.  6). 
These results imply that not only are Kir6.1 subunits 
normally expressed in the islet but that GOF mutations 
can reduce the glucose dependence of KATP conduc-
tance and hence of insulin secretion.
Diabetic mice and patients with KATP-GOF mutations 
respond to sulfonylurea drugs
The high sensitivity of Kir6.2/SUR1 channels to sulfo-
nylurea inhibition has led to a dramatic change in 
therapy for NDM, with most patients successfully trans-
ferring from injected insulin therapy to sulfonylurea 
tablets (Hattersley and Ashcroft, 2005; Pearson et al., 
2006; Masia et al., 2007; Wambach et al., 2010) or even 
being initiated on sulfonylurea therapy (Wambach et 
al., 2010; Marshall et al., 2015). However, many Kir6.2-
GOF mutations also exhibit reduced sensitivity to sul-
fonylureas (Koster et al., 2005), which may contribute 
to the generally observed requirement for relatively 
high doses of sulfonylureas in treatment of NDM pa-
tients (Hattersley and Ashcroft, 2005; Pearson et al., 
2006). The involvement of Kir6.1 subunits in β cell 
KATP channels has potentially important implications 
for KATP pharmacologies in the treatment of diabetes 
and the possibility that isoform-specific blockers of 
Figure 6. Reduced glucose sensitivity of KAtP conductance in 
Kir6.1-GoF islets. (A) Glucose- and glibenclamide-dependent 
Rb+ effluxes from BAC-Kir6.1[WT] (blue) and BAC-Kir6.1[GD] 
(pink) islets. (B) Rate constant for Rb+ efflux at each condition 
(ktest), normalized to rate constant in 1 mM glucose (k1G), in BAC-
Kir6.1[WT] and BAC-Kir6.1[GD] islets. Data represent mean ± 
SEM, n = 4 mice (n > 50 islets per sample) in each group. 
Figure 5. Impaired glucose-dependent insulin secretion 
in BAc-Kir6.1[Gd] transgenic mice. Glucose-dependent in-
sulin secretion on isolated islets from BAC-Kir6.1[GD] and 
BAC-Kir6.1[WT] mice. Batches of 10 islets were statically prein-
cubated in low glucose and then incubated in various glucose 
concentrations, or in glibenclamide, or in KCl for 1 h. Data rep-
resent mean ± SEM, n = 4–5 mice in each group. Significant 
differences (*, P < 0.05) between transgenic and control litter-
mates under the same condition are indicated (t test).
o
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these channels (Wellman et al., 1999) may need to be 
considered in the future. Although no mutations in 
the Kir6.1-encoding gene (KCNJ8) located on chro-
mosome 12p12 have yet been identified in diabetic pa-
tients, multiple studies have suggested linkage to 
diabetes mapping to chromosome 12p (Ng et al., 2004; 
Wiltshire et al., 2004). Further studies will be necessary 
to confirm any linkage between Kir6.1 and glucose in-
tolerance or diabetes.
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